Advertisement

Topics

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

2018-10-16 12:40:22 | BioPortfolio

Published on BioPortfolio: 2018-10-16T12:40:22-0400

Clinical Trials [4181 Associated Clinical Trials listed on BioPortfolio]

Phase IV Clinical Trial of an Influenza Split Vaccine Anflu

To evaluate the safety and immunogenicity of the three consecutive lots of an seasonal split influenza vaccine Anflu in adults, a randomized, double-blind and controlled clinical trial was...

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

It is the aim of the present study to compare the immunogenicity induced by a laser-assisted epidermally administered seasonal influenza vaccine to an intradermally administered seasonal i...

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

This is a trial for annual registration of the updated seasonal influenza vaccine formulation.

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

Every year the human population suffers from seasonal outbreaks of influenza resulting in both illness and death. However, the rates of illness and death from seasonal outbreaks are signif...

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)

PubMed Articles [3303 Associated PubMed Articles listed on BioPortfolio]

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

Children are susceptible to severe influenza infections and facilitate community transmission. One potential strategy to improve vaccine immunogenicity in children against seasonal influenza involves ...

Seasonal influenza vaccine effectiveness at primary care level, Hong Kong SAR, 2017/2018 winter.

The 2017/18 winter influenza season in Hong Kong SAR started in early January 2018, predominated by influenza B/Yamagata. We collaborated with private medical practitioners of our sentinel surveillanc...

Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019.

In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (https://www.cdc.gov/flu/protect/whoshouldvax.htm). Effectiveness of seasonal influe...

Perceptions of Seasonal Influenza and Pneumococcal Vaccines Among Older Chinese Adults.

Seasonal influenza can lead to pneumonia. In Hong Kong, deaths from pneumonia increased steadily from 2001 to 2015, and pneumonia was the second most common cause of death between 2012 and 2015. The s...

Redefining influenza seasonality at a global scale and aligning it to the influenza vaccine manufacturing cycle: a descriptive time series analysis.

Annual seasonal influenza vaccine manufacturing cycles align with temperate country seasonality in each hemisphere, yet influenza seasonality is poorly defined for many countries. The study introduces...

Medical and Biotech [MESH] Definitions

Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.

Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.

Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.

A subtype of INFLUENZA A VIRUS that is highly virulent in poultry and wild birds, but shows varying degrees of pathogenicity in mice. The H5N8 virus subtype has a polybasic amino acid motif at the HA cleavage site which explains its pathogenicity in birds, and expresses surface proteins HEMAGGLUTININ 5 and NEURAMINIDASE 8 which are typical of Highly Pathogenic Avian Influenza viruses.

A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 1 and neuraminidase 2. It is endemic in both human and pig populations.

More From BioPortfolio on "Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial